Evidence map›Paper›PMID 36675634›Full record

ArticleJournal of clinical medicine2023

Estimating Prevalence and Characteristics of Statin Intolerance among High and Very High Cardiovascular Risk Patients in Germany (2017 to 2020).

Klaus G Parhofer, Anastassia Anastassopoulou, Henry Calver, Christian Becker, Anirudh S Rathore, Raj Dave, Cosmin Zamfir

Abstract read
In one paragraph

Article in Journal of clinical medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Klaus G ParhoferLudwig Maximilians University, Medical Clinic IV, Großhadern, 81377 Munich, Germany.ORCID 0000-0001-9873-0412
Anastassia AnastassopoulouDaiichi Sankyo Europe GmbH, Zielstattstraße 48, 81379 Munich, Germany.
Henry CalverIQVIA, London W2 1AF, UK.
Christian BeckerDaiichi Sankyo Germany GmbH, Zielstattstraße 48, 81379 Munich, Germany.
Anirudh S RathoreIQVIA, London W2 1AF, UK.
Raj DaveIQVIA, Bangalore 560103, India.
Cosmin ZamfirIQVIA, 60549 Frankfurt, Germany.

Funding

Daiichi Sankyo Europe GmbH, Munich, Germany. 2861463-DSE-Value-Statin intolerance I
6 · The paper itself

Abstract

Statin intolerance (SI) (partial and absolute) could lead to suboptimal lipid management. The lack of a widely accepted definition of SI results into poor understanding of patient profiles and characteristics. This study aims to estimate SI and better understand patient characteristics, as reflected in clinical practice in Germany using supervised machine learning (ML) techniques. This retrospective cohort study utilized patient records from an outpatient setting in Germany in the IQVIA™ Disease Analyzer. Patients with a high cardiovascular risk, atherosclerotic cardiovascular disease, or hypercholesterolemia, and those on lipid-lowering therapies between 2017 and 2020 were included, and categorized as having “absolute” or “partial” SI. ML techniques were applied to calibrate prevalence estimates, derived from different rules and levels of confidence (high and low). The study included 292,603 patients, 6.4% and 2.8% had with high confidence absolute and partial SI, respectively. After deploying ML, SI prevalence increased approximately by 27% and 57% (p < 0.00001) in absolute and partial SI, respectively, eliciting a maximum estimate of 12.5% SI with high confidence. The use of advanced analytics to provide a complementary perspective to current prevalence estimates may inform the identification, optimal treatment, and pragmatic, patient-centered management of SI in Germany.

Indexed as

advanced analyticscardiovascular risklipid-lowering therapyprevalencestatin intolerancesupervised machine learning

Identifiers

PMID36675634
PMCPMC9864390

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.